![Quiver Logo](/static/img/logo-icon.png)
![ZVSA logo](https://quiver-logos.s3.us-east-2.amazonaws.com/zvsa.png)
ZyVersa Therapeutics, Inc. Common Stock
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ZVSA Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of ZVSA by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ZVSA's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to ZVSA
Recent picks made for ZVSA stock on CNBC
ETFs with the largest estimated holdings in ZVSA
Flights by private jets registered to ZVSA
![Quiver Logo](/static/img/logo-icon.png)